Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.

Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence ...

This week’s news from the life sciences includes Eli Lilly's investment in a Cambridge-Singapore biotech, Stealth ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.

There's no playbook for how to be competitive in artificial intelligence (AI) as a big pharma company, but Eli Lilly (NYSE: LLY) is taking a shot at developing one. With the appointment of a new chief ...

Sanofi has struck a deal in the hotly competitive radiopharmaceuticals sector, buying a $300mn stake in a subsidiary of French nuclear fuel company Orano that is developing a new cancer treatment.

The U.K. will study whether Lilly's weight loss drug can get people back to work and help tackle long-term sickness ...

Severe malnutrition is treated with ready-to-use therapeutic food, a paste combining peanuts, sugar, milk powder, oil, ...

Unfortunately, many of our elected leaders today undervalue the role of patents to progress the science of drug discovery and ...

Britain will study whether the use of Eli Lilly’s weight loss drug can get people back into work and help tackle the high ...